THE REATA MISSION
At Reata Pharmaceuticals, our mission is to develop innovative therapies that change patients’ lives for the better.
COMMITTED TO MAKING A POSITIVE IMPACT
Reata is focused on developing novel therapies for life threatening diseases that have few or no treatment options…
Learn More
FOCUSED ON CELLULAR METABOLISM & INFLAMMATION
Nrf2 activators exhibit broad, anti-inflammatory, anti-fibrotic, and promitochondrial activity in vitro and have many potential clinical applications1-3… 
Learn More
EXTENSIVE AND PROMISING PIPELINE
Our product candidates have the potential to treat patients with high unmet medical need…
Learn More
Our Pipeline
Reata’s development programs have created a robust pipeline of drug candidates for the treatment of serious, life-threatening diseases. Find out more here.
PIVOTAL PROGRAMS
Discovery
Preclinical
Phase 1
Phase 2
Pivotal
Bard=bardoxolone methyl; CTD-PAH=connective tissue disease-associated pulmonary arterial hypertension; Omav=omaveloxolone; ADPKD=autosomal dominant polycystic kidney disease.
Bardoxolone methyl and omaveloxolone are investigational drugs. Safety and efficacy have not been established by any agency.
Committed to making a difference for patients and their families
References
- Chin M, Lee CY, Chuang JC, et al. Bardoxolone methyl analogs RTA 405 and dh404 are well tolerated and exhibit efficacy in rodent models of type 2 diabetes and obesity. Am J Physiol Renal Physiol. 2013;304(12):F1438-F1446.
- Tan SM, Sharma A, Stefanovic N, et al. Derivative of bardoxolone methyl, dh404, in an inverse dose-dependent manner lessens diabetes-associated atherosclerosis and improves diabetic kidney disease. Diabetes. 2014;63(9):3091-3103.
- Abeti R, Baccaro A, Esteras N, Giunti P. Novel Nrf2-inducer prevents mitochondrial defects and oxidative stress in Friedreich’s ataxia models. Front Cell Neurosci. 2018;12:188.
